Allogeneic NK cells

Phase 1Cell therapy

AArtiva Biotherapeutics, Inc.

Allogeneic NK cells is one of 48 biologic programs targeting Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Non-Hodgkin LymphomaNot yet recruiting

LymphomaPhase 1

Active, not recruiting

Non-Hodgkin LymphomaPhase 1

Not yet recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Velban

EEastern Cooperative Oncology Group

Preclinical

15 2

Zofran

Novartis

Preclinical

2 3

Norvir

AbbVie

Preclinical

1 4

Tafasitamab

Incyte

Preclinical

7 5

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

1 7

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

PEG-Intron

1 9

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

3 10

VP-16

FFundamenta Therapeutics, Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Not yet recruiting

Non-Hodgkin Lymphoma

NCT07225439

Q1 2029

Phase 2Recruiting

Rheumatologic Disease

NCT06991114

Clinical

Trials by Indication[1]

Lymphoma1 trial

Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor

Completed·SSeoul National University Hospital·Phase 1·NCT01212341·18 enrolled

Rheumatologic Disease1 trial

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Recruiting·AArtiva Biotherapeutics, Inc.·Phase 2·NCT06991114·90 enrolled

Non-Hodgkin Lymphoma1 trial

Phase I Clinical Trial of Rituximab (Rtx) and Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma

Not yet recruiting·PPaolo Caimi, MD·Phase 1·NCT07225439·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Allogeneic NK cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Allogeneic NK cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Allogeneic NK cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Artiva Biotherapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: AArtiva Biotherapeutics, Inc.

Allogeneic NK cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2029

Trials by Indication[1]

Lymphoma1 trial

Rheumatologic Disease1 trial

Non-Hodgkin Lymphoma1 trial

References

Drug Info

Quick Facts

Related News